NVS•Novartis said remibrutinib reduced relapses versus teriflunomide in the Phase III REMODEL-1 and REMODEL-2 trials for relapsing multiple sclerosis. The company plans global regulatory submissions.
Novartis presented positive Phase III REMODEL-1 and REMODEL-2 results for remibrutinib in relapsing multiple sclerosis on October 23, 2026. The oral treatment reduced relapses versus teriflunomide, and a clinically meaningful delay in disability progression reached nominal statistical significance.
No liver safety signal emerged, and treatment discontinuations due to adverse events were lower than with teriflunomide. Results were presented at MSToronto2026 and published in The Lancet; global regulatory submissions are planned.
